CY1121695T1 - Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit - Google Patents

Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit

Info

Publication number
CY1121695T1
CY1121695T1 CY20191100671T CY191100671T CY1121695T1 CY 1121695 T1 CY1121695 T1 CY 1121695T1 CY 20191100671 T CY20191100671 T CY 20191100671T CY 191100671 T CY191100671 T CY 191100671T CY 1121695 T1 CY1121695 T1 CY 1121695T1
Authority
CY
Cyprus
Prior art keywords
compounds
kinase inhibitors
compositions
kit
kit kinase
Prior art date
Application number
CY20191100671T
Other languages
Greek (el)
English (en)
Inventor
Vince Yeh
Xiaolin Li
Xiaodong Liu
Jon Loren
Valentina Molteni
Juliet Nabakka
Bao Nguyen
Hank Michael James Petrassi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1121695T1 publication Critical patent/CY1121695T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/04Drugs for disorders of the respiratory system for throat disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20191100671T 2011-09-01 2019-06-27 Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit CY1121695T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530028P 2011-09-01 2011-09-01
PCT/US2012/052621 WO2013033070A1 (en) 2011-09-01 2012-08-28 COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
CY1121695T1 true CY1121695T1 (el) 2020-07-31

Family

ID=46829898

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100671T CY1121695T1 (el) 2011-09-01 2019-06-27 Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit

Country Status (42)

Country Link
US (1) US9199981B2 (enExample)
EP (1) EP2751102B1 (enExample)
JP (1) JP6117208B2 (enExample)
KR (1) KR101959590B1 (enExample)
CN (1) CN103764653B (enExample)
AP (1) AP2014007494A0 (enExample)
AR (1) AR087752A1 (enExample)
AU (1) AU2012300248B2 (enExample)
BR (1) BR112014004504B1 (enExample)
CA (1) CA2845159C (enExample)
CL (1) CL2014000494A1 (enExample)
CO (1) CO6900140A2 (enExample)
CR (1) CR20140106A (enExample)
CU (1) CU20140023A7 (enExample)
CY (1) CY1121695T1 (enExample)
DK (1) DK2751102T3 (enExample)
EA (1) EA024293B1 (enExample)
ES (1) ES2732671T3 (enExample)
GT (1) GT201400036A (enExample)
HR (1) HRP20191140T1 (enExample)
HU (1) HUE044373T2 (enExample)
IL (1) IL231226A (enExample)
JO (1) JOP20120246B1 (enExample)
LT (1) LT2751102T (enExample)
MA (1) MA35459B1 (enExample)
ME (1) ME03395B (enExample)
MX (1) MX342329B (enExample)
MY (1) MY167245A (enExample)
PE (1) PE20141033A1 (enExample)
PH (1) PH12014500351B1 (enExample)
PL (1) PL2751102T3 (enExample)
PT (1) PT2751102T (enExample)
RS (1) RS59025B1 (enExample)
SG (1) SG2014011050A (enExample)
SI (1) SI2751102T1 (enExample)
TN (1) TN2014000061A1 (enExample)
TR (1) TR201909189T4 (enExample)
TW (1) TWI543981B (enExample)
UA (1) UA110841C2 (enExample)
UY (1) UY34300A (enExample)
WO (1) WO2013033070A1 (enExample)
ZA (1) ZA201401113B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033167A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
BR112015000675B1 (pt) * 2012-07-13 2022-07-12 UCB Biopharma SRL Derivados de imidazopiridina como moduladores da atividade de tnf
CA2897651C (en) 2013-01-10 2021-09-21 Pulmokine, Inc. Non-selective kinase inhibitors
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CA2926793C (en) 2013-10-11 2022-11-22 Lawrence S. ZISMAN Spray-dry formulations for treating pulmonary arterial hypertension
WO2015082411A1 (de) * 2013-12-05 2015-06-11 Bayer Pharma Aktiengesellschaft Aryl- und hetaryl-substituierte imidazo[1,2-a]pyridin-3-carboxamide und ihre verwendung
CN103965190A (zh) * 2014-05-20 2014-08-06 定陶县友帮化工有限公司 一种咪唑并[1,2-a]吡啶-3-甲酸的合成方法
WO2017001660A1 (en) 2015-07-02 2017-01-05 Janssen Sciences Ireland Uc Antibacterial compounds
US10059708B2 (en) * 2016-04-26 2018-08-28 Northwestern University Therapeutic targeting of the interleukin 1 receptor-associated kinase 4 (IRAK4) in leukemias characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)
JP2019518050A (ja) 2016-06-16 2019-06-27 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌薬としての複素環式化合物
JP2019518046A (ja) 2016-06-16 2019-06-27 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗菌薬としての複素環式化合物
CN110087653A (zh) 2016-10-27 2019-08-02 普尔莫凯恩股份有限公司 用于治疗肺高血压的组合疗法
WO2018158280A1 (en) 2017-03-01 2018-09-07 Janssen Sciences Ireland Uc Combination therapy
CN111039946A (zh) * 2018-10-15 2020-04-21 上海轶诺药业有限公司 一类咪唑并芳环类化合物的制备和应用
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3969453A4 (en) * 2019-05-13 2023-01-18 Novartis AG CRYSTALLINE FORMS OF N-(5-(5-((1R,2S)-2-FLUOROCYCLOPROPYL)-1,2,4-OXADIAZOL-3-YL)-2-METHYLPHENYL)IMIDAZO[1,2-A]PYRIDINE- 3-CARBOXAMIDE
WO2021048342A1 (en) 2019-09-13 2021-03-18 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021187486A1 (ja) * 2020-03-17 2021-09-23 大日本住友製薬株式会社 オキサジアゾール誘導体
US11767319B2 (en) * 2020-07-15 2023-09-26 Third Harmonic Bio, Inc. Crystalline forms of a selective c-kit kinase inhibitor
WO2022106615A1 (en) 2020-11-19 2022-05-27 Novartis Ag Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
JP2023551434A (ja) * 2020-11-19 2023-12-08 サード ハーモニック バイオ, インコーポレイテッド 選択的c-kitキナーゼ阻害剤の医薬組成物ならびにその作製および使用のための方法
WO2022182982A1 (en) * 2021-02-26 2022-09-01 Third Harmonic Bio, Inc. Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor
KR20230157400A (ko) 2021-03-16 2023-11-16 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항박테리아성 화합물
CN117440958A (zh) * 2021-03-17 2024-01-23 爱尔兰詹森科学公司 抗菌化合物
CA3211592A1 (en) 2021-03-17 2022-09-22 Jerome Emile Georges Guillemont Antibacterial compounds
CN118159543A (zh) 2021-10-28 2024-06-07 爱尔兰詹森科学公司 在治疗细菌感染中使用的咪唑并吡啶酰胺和相关化合物
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
KR20250121029A (ko) 2022-11-30 2025-08-11 블루프린트 메디신즈 코포레이션 두드러기 치료를 위한 야생형 c-kit 키나제 억제제로서의 n-페닐-피라졸로[1,5-a]피리딘-3-카르복사미드 유도체
KR20250129682A (ko) * 2022-12-07 2025-08-29 써드 하모닉 바이오, 인크. C-kit 키나제 억제제로서의 화합물 및 조성물
CN120677155A (zh) * 2022-12-07 2025-09-19 第三谐波生物股份有限公司 作为c-Kit激酶抑制剂的化合物和组合物
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025024503A1 (en) * 2023-07-25 2025-01-30 Enanta Pharmaceuticals, Inc. PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
TW202523302A (zh) 2023-11-02 2025-06-16 美商阿克思生物科學有限公司 噻唑化合物及其使用方法
WO2025146196A1 (zh) * 2024-01-04 2025-07-10 上海翰森生物医药科技有限公司 多环类衍生物抑制剂、其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518993D0 (en) * 1995-09-16 1995-11-15 Agrevo Uk Ltd Fungicides
US20070072861A1 (en) * 2000-03-27 2007-03-29 Barbara Roniker Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
AU2003251561A1 (en) 2002-06-20 2004-01-06 Beacon Looms, Inc. Knitted electrical conductor fabric
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
KR20120049397A (ko) 2006-11-03 2012-05-16 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
AR083855A1 (es) * 2010-11-15 2013-03-27 Abbott Lab Inhibidores de nampt y rock
JP2014525450A (ja) * 2011-09-01 2014-09-29 アイアールエム・リミテッド・ライアビリティ・カンパニー c−Kitキナーゼ阻害剤としての化合物および組成物
WO2013033167A1 (en) * 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
JP2014525447A (ja) * 2011-09-01 2014-09-29 アイアールエム・リミテッド・ライアビリティ・カンパニー c−Kitキナーゼ阻害剤としての化合物および組成物

Also Published As

Publication number Publication date
PH12014500351A1 (en) 2014-04-07
HUE044373T2 (hu) 2019-10-28
CA2845159A1 (en) 2013-03-07
AR087752A1 (es) 2014-04-16
MY167245A (en) 2018-08-14
MX342329B (es) 2016-09-26
MX2014002482A (es) 2014-11-25
UY34300A (es) 2013-04-05
WO2013033070A1 (en) 2013-03-07
BR112014004504A2 (pt) 2017-03-28
IL231226A0 (en) 2014-04-30
US9199981B2 (en) 2015-12-01
SG2014011050A (en) 2014-08-28
LT2751102T (lt) 2019-07-10
KR101959590B1 (ko) 2019-03-18
PL2751102T3 (pl) 2019-09-30
NZ621092A (en) 2016-06-24
TR201909189T4 (tr) 2019-07-22
CO6900140A2 (es) 2014-03-20
IL231226A (en) 2017-03-30
CA2845159C (en) 2020-11-03
BR112014004504B1 (pt) 2022-03-22
KR20140071382A (ko) 2014-06-11
TN2014000061A1 (en) 2015-07-01
CL2014000494A1 (es) 2014-09-05
PT2751102T (pt) 2019-07-10
PH12014500351B1 (en) 2019-04-03
GT201400036A (es) 2015-06-02
CN103764653A (zh) 2014-04-30
EP2751102B1 (en) 2019-03-27
AP2014007494A0 (en) 2014-03-31
JOP20120246B1 (ar) 2022-03-14
AU2012300248B2 (en) 2015-08-27
DK2751102T3 (da) 2019-07-01
TWI543981B (zh) 2016-08-01
HRP20191140T1 (hr) 2019-09-20
JP2014525444A (ja) 2014-09-29
AU2012300248A1 (en) 2014-04-17
JP6117208B2 (ja) 2017-04-19
CR20140106A (es) 2014-05-02
EA024293B1 (ru) 2016-09-30
EA201490540A1 (ru) 2014-06-30
EP2751102A1 (en) 2014-07-09
RS59025B1 (sr) 2019-08-30
MA35459B1 (fr) 2014-09-01
CU20140023A7 (es) 2014-04-24
ME03395B (me) 2020-01-20
TW201313716A (zh) 2013-04-01
ZA201401113B (en) 2015-10-28
ES2732671T3 (es) 2019-11-25
CN103764653B (zh) 2015-12-02
US20130059846A1 (en) 2013-03-07
PE20141033A1 (es) 2014-08-30
SI2751102T1 (sl) 2019-08-30
UA110841C2 (uk) 2016-02-25

Similar Documents

Publication Publication Date Title
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
CY1125436T1 (el) Αναστολεις dna-pk
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1122556T1 (el) Υποκατεστημενα αναλογα ν-φαινυλπυριμιδιν-2- αμινης ως αναστολεις της κινασης axl
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
EA201490545A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ С-Kit
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1120246T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1121511T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
CY1120692T1 (el) Καινοφανη παραγωγα βενζιμιδαζολης ως αναστολεις κινασων
EA201490537A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ C-Kit
CY1122176T1 (el) Αλατα ενος αναστολεα κινασης υποδοχεα επιδερμικου αυξητικου παραγοντα
EA201490542A1 (ru) Соединения и композиции в качестве pdgfr киназных ингибиторов
BRPI0811617A2 (pt) derivados de primidina e composições como inibidores de c-kit e pdgfr quinase.
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
CY1119605T1 (el) Παραγωγα 5-αρυλο ή 5-ετεροαρυλο υποκατεστημενου 3-υδροξυπυριδιν-2-υλ-καρβονυλαμινο-αλκανοϊκου οξεος και αλατα αυτων καθως και παρασκευη τους απο τα αντιστοιχα παραγωγα 3-υδροξυ-πικολινικου οξεος
MX382991B (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
MX2019008122A (es) Derivados de aminas heterociclicas que inhiben la transduccion de se?al mediada por cinasa asociada con el receptor de interleucina-1.
MX385616B (es) Inhibidores de cdk
BR112014013974A8 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201290642A1 (ru) Соединения и способы